07Aug/13

First Patient Treated with Civacir® after Hepatitis C Induced Liver … – MarketWatch (press release)

First Patient Treated with Civacir® after Hepatitis C Induced Liver
MarketWatch (press release)
Civacir, a 10 % hepatitis C hyperimmune globulin developed and produced at Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG, is being used in a clinical trial in North America in patients undergoing liver transplantation as
Biotest commences phase III trial of hepatitis C therapyZenopa

all 2 news articles »

07Aug/13

First Patient Treated with Civacir® after Hepatitis C Induced Liver … – PR Newswire (press release)

First Patient Treated with Civacir® after Hepatitis C Induced Liver
PR Newswire (press release)
After treatment with virostatics over several weeks, the first patient underwent liver transplantation and subsequently was treated with the Civacir in the Phase III clinical trial. Civacir, a 10 % hepatitis C hyperimmune globulin developed and
Biotest commences phase III trial of hepatitis C therapyZenopa

all 2 news articles »